Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Study ID
NCT01573468

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

TESEGAST

Trial Summary

This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.

More informations

Trial Starting Date

Apr 30,2012

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

580